Centre for Human Drug Research, Netherlands
29
4
5
17
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
10.3%
3 terminated/withdrawn out of 29 trials
85.0%
-1.5% vs industry average
10%
3 trials in Phase 3/4
6%
1 of 17 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (29)
Deep Phenotyping of CIndU
Role: lead
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Role: collaborator
An Explorative Psoriasis Biomarker Study
Role: lead
Skin Barrier and Microbiome of CTCL Patients
Role: lead
A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy Participants
Role: collaborator
Study of UB-312 in Healthy Participants and Parkinson's Disease Patients
Role: collaborator
Single and Repeat Doses of DMT in Healthy Subjects
Role: collaborator
MAD Study of NX210c
Role: collaborator
Older Adults Exercising On Time
Role: collaborator
Deep Phenotyping of Cutaneous Lupus Erythematosus
Role: lead
Population PK/PD of Off Label Drugs in Premature Neonates
Role: collaborator
[18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer
Role: collaborator
Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy
Role: collaborator
Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma
Role: collaborator
Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides
Role: lead
Bleomycin Jet Injections in Keloids
Role: collaborator
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
Role: collaborator
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
Role: collaborator
Digital Biotyping of FSHD Patients and Controls
Role: lead
CyPep-1 in Cutaneous Warts
Role: lead